Department of General Surgery, University Hospital Aintree, United Kingdom.
Eur J Surg Oncol. 2010 Jan;36(1):52-7. doi: 10.1016/j.ejso.2009.09.004. Epub 2009 Oct 29.
Hepatic steatosis (HS) is as an independent risk factor for morbidity and mortality post-hepatectomy. Recent studies report significant correlation between chemotherapy (now frequently employed pre-hepatectomy for colorectal liver metastases (CRLM)), HS and steatohepatitis. Furthermore, raised body mass index (BMI) predisposes to HS. However, no previous study has analysed the effect of HS on long-term survival.
A retrospective analysis of a prospective consecutive cohort of 102 patients undergoing hepatectomy with 60 months follow-up data was performed. Resection specimens were examined histologically and the degree of steatosis graded accordingly. The data was compared to BMIs and other clinical characteristics. Statistical analyses included log-rank, contingency, logistic regression and Fisher's exact tests.
No detectable fatty change in 27 patients; 1 patient had cirrhosis; 57 had HS: 26 graded mild; 10 moderate, 21 severe and 17 not graded. 1 patient (BMI 29.5 kg/m(2)) had steatohepatitis but survived surgery. No significant difference in median survival between patients with and without HS (28.6 vs. 32.3 months, log-rank p>0.05). Results were similar between patients with BMI<25 and BMI>or=25 (32.3 vs. 36.8 months, log-rank p>0.05). Analyses of BMI against steatosis grade showed that patients with a higher BMI were at an increased risk of having a more severe HS (logistic regression, p<0.01; Fisher's exact, p<0.01). Contingency analyses on the influence of diabetes, chemotherapy and increasing number of risk factors on the likelihood of obtaining HS were insignificant (Fisher's exact, all p>0.05).
While patients with higher body mass index values are at increased risk of having more severe hepatic steatosis, neither BMI nor hepatic steatosis significantly influences long-term survival. We conclude therefore that neither obesity nor hepatic steatosis has significant prognostic relevance on long-term survival of CRLM patients undergoing hepatectomy.
肝脂肪变性(HS)是肝切除术后发病率和死亡率的独立危险因素。最近的研究报告称,化疗(目前常用于结直肠癌肝转移(CRLM)的术前)、HS 和脂肪性肝炎之间存在显著相关性。此外,升高的体重指数(BMI)易导致 HS。然而,以前没有研究分析 HS 对长期生存的影响。
对 102 例接受肝切除术并随访 60 个月的前瞻性连续队列进行回顾性分析。对切除标本进行组织学检查,并相应地对脂肪变性程度进行分级。将数据与 BMI 和其他临床特征进行比较。统计分析包括对数秩检验、列联表、逻辑回归和 Fisher 精确检验。
27 例患者无明显脂肪变化;1 例患者有肝硬化;57 例患者有 HS:26 例轻度;10 例中度,21 例重度,17 例未分级。1 例(BMI 为 29.5kg/m²)患有脂肪性肝炎,但手术存活。有 HS 和无 HS 患者的中位生存期无显著差异(28.6 与 32.3 个月,对数秩检验 p>0.05)。BMI<25 和 BMI≥25 的患者结果相似(32.3 与 36.8 个月,对数秩检验 p>0.05)。BMI 与脂肪变性分级的分析表明,BMI 较高的患者发生更严重 HS 的风险增加(逻辑回归,p<0.01;Fisher 精确检验,p<0.01)。糖尿病、化疗和危险因素数量增加对获得 HS 的可能性的影响的列联表分析无统计学意义(Fisher 精确检验,均 p>0.05)。
虽然 BMI 值较高的患者发生更严重 HS 的风险增加,但 BMI 或 HS 均不会显著影响长期生存。因此,我们得出结论,肥胖或 HS 对接受肝切除术的 CRLM 患者的长期生存均无显著预后意义。